Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a developer and commercial supplier of a diversified portfolio of advanced drug delivery systems. We serve as a partner to pharmaceutical and biotechnology companies seeking to optimize drug lifecycles and generate brand differentiation within competitive therapeutic markets.

Our streamlined business structure, advanced operational capabilities, state-of-the-art facilities, world-class team and stringent quality systems enable us to respond to customer requirements with unparalleled speed, agility and reliability.

We have developed a rich portfolio of primary drug containers and other advanced delivery systems in direct response to unmet market needs for injectable drugs including biologics.

Our proprietary technology platforms include prefilled syringes with integrated safety features, patient self-injection systems and novel devices for targeted organ delivery. The Unifill syringe, the world's first and only ready-to-fill syringe with integrated safety features, sits at the leading edge of this unique technology platform of primary containers that is suitable for use with virtually all prefilled drugs supplied in either a liquid stable form or lyophilized for reconstitution. Additional variants within the Unifill range of prefilled syringes include the Unifill Select with attachable needles, and the Unifill EZMix available in dual or multi-chamber formats.

Our self-administration device platforms include auto-injectors and subcutaneous auto-infusion systems with true end-of-dose indicators that enable patients to intuitively inject viscous or large-volume drugs. Any device sourced from our portfolio can be custom-designed in collaboration with the customoer to address specific molecular or patient requirements.